Failure of neutral-red photodynamic inactivation in recurrent herpes simplex virus infections.
Because photodynamic inactivation of herpes simplex virus infections may not be free of hazard, the efficacy of photodynamic inactivation with neutral red and light was evaluated in a placebo-controlled study of 170 episodes of recurrent herpes simplex virus infection in 96 patients. The preparation of neutral red that was used was shown to photoinactivate herpes simplex virus in vitro, but had no significant effect on the rate of resolution of herpetic lesions (P greater than 0.10) or on the frequency of subsequent recurrences (P greater than 0.10), except for orolabial lesions, in which an adverse effect on the rate of subsequent recurrences was observed (P less than 0.05). In the absence of demonstrated efficacy, the routine use of neutral red and light in patients with recurrent herpes simplex virus infections should be discontinued. Furthermore, other photoactive dyes should not be used until their efficacy has been demonstrated by suitably controlled clinical trials.
D000287:Administration, Topical; D000293:Adolescent; D000328:Adult; D000368:Aged; D002648:Child; D002675:Child, Preschool; D002986:Clinical Trials as Topic; D005260:Female; D005831:Genital Diseases, Female / Q000188:drug therapy / Q000628:therapy; D005832:Genital Diseases, Male / Q000188:drug therapy / Q000628:therapy; D006560:Herpes Labialis / Q000188:drug therapy / Q000628:therapy; D006561:Herpes Simplex / Q000188:drug therapy / Q000382:microbiology / Q000628:therapy*; D006801:Humans; D008297:Male; D008875:Middle Aged; D009499:Neutral Red / Q000008:administration & dosage / Q000627:therapeutic use*; D010619:Phenazines / Q000627:therapeutic use*; D010637:Phenolsulfonphthalein / Q000008:administration & dosage; D010789:Phototherapy; D010919:Placebos; D012008:Recurrence; D018139:Simplexvirus / Q000302:isolation & purification
D010619:Phenazines; D010919:Placebos; D009499:Neutral Red; D010637:Phenolsulfonphthalein